Scaling Up ADC Payloads
Webinar Date/Time: Thu, Oct 27, 2022 11:00 AM EDT
Join our latest webinar ‘Scaling up payload manufacturing for blockbuster ADCs.
Register free: https://www.pharmtech.com/pt_w/payloads
Event Overview:
Antibody-drug conjugates are a targeted approach to the treatment of cancer. As more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.
- Market drivers
- Design concepts
- Facility overview
Key Learning Objectives:
- Key market trends
- Lonza’s approach to lifecycle investment
- Leadership in highly-potent API facility and process design
Who Should Attend:
- Key clients / potential clients from the ADC arena, covering all disciplines from biologics/ bioconjugation and payload-linker
Charles Johnson
Senior Director
Commercial Development
Lonza Small Molecules
Charles Johnson is the senior director of commercial development for Lonza Small Molecules. Charles has more than 20 years of experience in the pharmaceutical sector and specializes in antibody-drug conjugates. Prior to joining Lonza, Charles was CEO of ADC Biotechnology, which focuses on innovative immobilization technologies for protein conjugation and purification applications.
Register free: https://www.pharmtech.com/pt_w/payloads
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
